Skip to main content

Advertisement

SpringerLink
Log in

Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The topic of drug safety has received great attention in recent years. Pharmacoepidemiology is the study of the use and effects of medicines in large populations using epidemiological methods. Pharmacoepidemiologic research can fill the knowledge gaps due to the limitations of existing pharmacovigilance systems that rely on randomised controlled trials and voluntary reporting. This review discusses the present state of pharmacoepidemiologic research in Australia. In Australia, linking administrative data on use of medications and medical services is possible to a certain extent. Data from patient registries with respect to rheumatology are also available. These data are valuable for better understanding of the beneficial and adverse effects of medicines. Opportunities and challenges of using these data sources to address issues from clinical pharmacology are also highlighted. Australia is well-placed internationally to make major contributions to the knowledge base of outcomes of medicines in the real-world setting. Developments in pharmacoepidemiology are critical to clinicians treating patients with rheumatic and other conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Australian Institute of Health and Welfare (2005) Arthritis and musculoskeletal conditions in Australia, 2005 AIHW Cat. No. PHE67. Australian Institute of Health and Welfare, Canberra

  2. Avorn J (2004) The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation. Pharmacoeconomics 22(Suppl 2):81–86

    Article  PubMed  Google Scholar 

  3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102

    Article  PubMed  CAS  Google Scholar 

  4. Topol EJ (2004) Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med 351:1707–1709

    Article  PubMed  CAS  Google Scholar 

  5. Hampton T (2005) Experts point to lessons learned from controversy over rofecoxib safety. JAMA 293:413–414

    Article  PubMed  CAS  Google Scholar 

  6. Krumholz HM, Ross JS, Presler AH, Egilman DS (2007) What have we learnt from Vioxx? BMJ 334:120–123

    Article  PubMed  Google Scholar 

  7. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471

    Article  PubMed  CAS  Google Scholar 

  8. Mangano DT, Tudor IC, Dietzel C (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354:353–365

    Article  PubMed  CAS  Google Scholar 

  9. Solomon DH, Glynn RJ, Levin R, Avorn J (2002) Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162:1099–1104

    Article  PubMed  CAS  Google Scholar 

  10. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 163:59–64

    Article  PubMed  CAS  Google Scholar 

  11. Waldman A, Kritharides L (2003) The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 63:139–152

    Article  PubMed  CAS  Google Scholar 

  12. Kelman CW, Pearson SA, Day RO, Holman CD, Kliewer EV, Henry DA (2007) Evaluating medicines: let’s use all the evidence. Med J Aust 186(5):249–252

    PubMed  Google Scholar 

  13. Hunter D (2006) First, gather the data. N Engl J Med 354:329–331

    Article  PubMed  CAS  Google Scholar 

  14. Brewer T, Colditz GA (1999) Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281:824–829

    Article  PubMed  CAS  Google Scholar 

  15. Boyd IW (2002) The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. Toxicology 181–182:99–102

    Article  PubMed  Google Scholar 

  16. Goldman SA (1998) Limitations and strengths of spontaneous reports data. Clin Ther 20(Suppl C):C40–C44

    Article  PubMed  CAS  Google Scholar 

  17. Australian Government Department of Health and Ageing (2002) The national strategy for quality use of medicines—executive summary. Australian Government Department of Health and Ageing, Canberra

    Google Scholar 

  18. Gram LE, Hallas J, Andersen M (2000) Pharmacovigilance based on prescription databases. Pharmacol Toxicol 86(Suppl 1):13–15

    Article  PubMed  CAS  Google Scholar 

  19. Food and Drug Administration (2008) Developing guidance on conducting scientifically sound pharmacoepidemiologic safety studies using large electronic healthcare data sets: public workshop: request for comments. Fed Regist 73:21963–21964

    Google Scholar 

  20. Strom BL (2005) Pharmacoepidemiology. Wiley, Chichester

    Google Scholar 

  21. Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 11:1215–1218

    Google Scholar 

  22. Evans JM, MacDonald TM (1997) Misclassification and selection bias in case–control studies using an automated database. Pharmacoepidemiol Drug Saf 6:313–318

    Article  PubMed  CAS  Google Scholar 

  23. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878–1886

    Article  PubMed  CAS  Google Scholar 

  24. Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Eng J Med 342:1887–1892

    Article  CAS  Google Scholar 

  25. Lu CY, Williams KM, Day RO (2007) Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J 37:601–606

    Article  PubMed  CAS  Google Scholar 

  26. Lu CY, Williams KM, Day RO (2007) The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Aust New Zealand Health Policy 4:2

    Article  PubMed  Google Scholar 

  27. Peterson GM, Sugden JE (1995) Educational program to improve the dosage prescribing of allopurinol. Med J Aust 162:74–77

    PubMed  CAS  Google Scholar 

  28. Breen CL, Degenhardt LJ, Bruno RB, Roxburgh AD, Jenkinson R (2004) The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injection drug users in Australia. Med J Aust 181:300–304

    PubMed  Google Scholar 

  29. O’Connell DL, Henry D, Tomlins R (1999) Randomised controlled trial of effect of feedback on general practitioners’ prescribing in Australia. BMJ 318:507–511

    PubMed  CAS  Google Scholar 

  30. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–1112

    PubMed  CAS  Google Scholar 

  31. Avorn J, Soumerai SB (1982) Use of a computer-based Medicaid drug data to analyze and correct inappropriate medication use. J Med Syst 6:377–386

    Article  PubMed  CAS  Google Scholar 

  32. Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V (1993) Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. Pharmacoeconomics 3:427–432

    Article  PubMed  CAS  Google Scholar 

  33. Australian Institute of Health and Welfare (2005) Australian hospital statistics 2003–04. Health Services Series no. 23. Cat. no. HSE 37. Australian Institute of Health and Welfare, Canberra.

  34. Lazaridis EN (1997) Database standardization, linkage, and the protection of privacy. Ann Intern Med 127:696

    PubMed  CAS  Google Scholar 

  35. Sibthorpe B, Kliewer E, Smith L (1995) Record linkage in Australian epidemiological research: health benefits, privacy safeguards and future potential. Aust J Public Health 19:250–256

    PubMed  CAS  Google Scholar 

  36. Mount CD, Kelman CW, Smith LR, Douglas RM (2000) An integrated electronic health record and information system for Australia? Med J Aust 172:25–27

    PubMed  CAS  Google Scholar 

  37. Australian Government Department of Veterans’ Affairs DVA Statistics. Australian Government Department of Veterans’ Affairs. Available from: http://www.dva.gov.au/media/publicat/statistics/. Accessed 12 Oct 2008

  38. Pearson SA, Ringland C, Lowinger J, Kelman C, Mant A (2005) Using secondary data sources to evaluate the impact of the Joint Heart Failure Program on health outcomes: report to the National Prescribing Service. Population Health and Use of Medicines Unit, University of New South Wales

  39. Roughead EE, Pratt N, Gilbert AL (2007) Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes. Br J Clin Pharmacol 64:100–104

    Article  PubMed  Google Scholar 

  40. Roughead EE, Barratt J, Gilbert AL, Peck R, Killer G (2008) Diabetes processes of care in the Australian veteran population. Diabetes Res Clin Pract 79:299–304

    Article  PubMed  Google Scholar 

  41. Roughead EE, McDermott B, Gilbert AL (2007) Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Aust N Z J Psychiatry 41:366–370

    Article  PubMed  Google Scholar 

  42. Roughead EE, Anderson B, Gilbert AL (2007) Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 37:402–405

    Article  PubMed  CAS  Google Scholar 

  43. Hillen J, Roughead E, Gilbert A, Rowett D, Azam R, Rossi S, Alderman C, Stocks N (2006) Data-driven patient-specific prescriber feedback; the Veterans’ MATES project. National Medicines Symposium

  44. Holman CD, Bass AJ, Rouse IL, Hobbs MS (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23:453–459

    Article  PubMed  CAS  Google Scholar 

  45. Kelman C, Smith L (2000) It’s time: record linkage—the vision and the reality. Aust N Z J Public Health 24:100–101

    Article  PubMed  CAS  Google Scholar 

  46. Kelman CW, Bass AJ, Holman CD (2002) Research use of linked health data—a best practice protocol. Aust N Z J Public Health 26:251–255

    Article  PubMed  CAS  Google Scholar 

  47. Brook EL, Rosman DL, Holman CD (2008) Public good through data linkage: measuring research outputs from the Western Australian Data Linkage System. Aust N Z J Public Health 32:19–23

    Article  PubMed  Google Scholar 

  48. Spilsbury K, Semmens JB, Saunders CM, Holman CD (2005) Long-term survival outcomes following breast cancer surgery in Western Australia. ANZ J Surg 75:625–630

    Article  PubMed  Google Scholar 

  49. Laurvick CL, Semmens JB, Leung YC, Holman CD (2003) Ovarian cancer in Western Australia (1982–1998): trends in surgical intervention and relative survival. Gynecol Oncol 88:141–148

    Article  PubMed  Google Scholar 

  50. Lawrence D, Jablensky AV, Holman CD, Pinder TJ (2000) Mortality in Western Australian psychiatric patients. Soc Psychiatry Psychiatr Epidemiol 35:341–347

    Article  PubMed  CAS  Google Scholar 

  51. Lawrence D, Holman CD, Jablensky AV, Fuller SA, Stoney AJ (2001) Increasing rates of suicide in Western Australian psychiatric patients: a record linkage study. Acta Psychiatr Scand 104:443–451

    Article  PubMed  CAS  Google Scholar 

  52. Kelman CW, Kortt MA, Becker NG, Li Z, Mathews JD, Guest CS, Holman CD (2003) Deep vein thrombosis and air travel: record linkage study. BMJ 327:1072

    Article  PubMed  CAS  Google Scholar 

  53. Hall SE, Bulsara CE, Bulsara MK, Leahy TG, Culbong MR, Hendrie D, Holman CD (2004) Treatment patterns for cancer in Western Australia: does being indigenous make a difference? Med J Aust 181:191–194

    PubMed  Google Scholar 

  54. Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, Meehan A, Henderson L, Wengier L, van den Haak R (2007) Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern Med J 37:591–600

    Article  PubMed  CAS  Google Scholar 

  55. Australian Rheumatology Association Database (2008) Database update: November 2008. Australian Rheumatology Association. Available from: http://www.rheumatology.org.au/. Accessed 12 Nov 2008

  56. Australian Rheumatology Association Database (2008) Six monthly aggregate report: May 2008. Australian Rheumatology Association. Available from: http://www.rheumatology.org.au/. 12 Nov 2008

  57. Briggs AM, Staples M, March L, Lassere M, Reid C, Henderson L, Wengier L, van den Haak R, Buchbinder R (2007) The rate of infection after six months of bDMARD therapy is greater than at initiation of therapy. Intern Med J 37(Suppl. 2):A38

    Google Scholar 

  58. Briggs AM, March L, Lassere M, Reid C, Portek I, Wengier L, van den Haak R, Henderson L, Buchbinder R (2007) Baseline comorbidity in Australian patients receiving biological therapy for rheumatoid arthritis. Intern Med J 37(Suppl. 2):A38

    Google Scholar 

  59. Schachna L, Oldroyd J, Buchbinder R, Staples M, Lassere M, Reid C, Briggs AM, Zochling J, Murphy B, Henderson L, van den Haak R, Hay N, Bond M, March L (2008) Comorbidities in an Australian population-based cohort of patients with ankylosing spondylitis commencing biological therapy: data from the Australian Rheumatology Association Database (ARAD). Intern Med J 38(Suppl. 2):A13

    Google Scholar 

  60. Graves SE, Davidson D, Ingerson L, Ryan P, Griffith EC, McDermott BF, McElroy HJ, Pratt NL (2004) The Australian Orthopaedic Association National Joint Replacement Registry. Med J Aust 180(5 Suppl):S31–S34

    PubMed  Google Scholar 

Download references

Acknowledgement

Dr. Lu is supported by an Australian National Health and Medical Research Council Training Public Health (Australia) Fellowship (Grant no. 456438).

Disclosures

None

Author information

Authors and Affiliations

  1. Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, GPO Box 2471, Adelaide, SA, 5001, Australia

    Christine Y. Lu

Authors
  1. Christine Y. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Y. Lu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, C.Y. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. Clin Rheumatol 28, 371–377 (2009). https://doi.org/10.1007/s10067-009-1102-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1102-6

Keywords

Search

Navigation